The following companies provided test kits to the first author's institution to help conduct this study: Abbott, Qiagen, Gen-Probe Incorporated, Genomica S.A.U., mtm Laboratories, NorChip, and Roche Diagnostics.
Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears†
Article first published online: 25 MAY 2010
Copyright © 2010 Wiley-Liss, Inc.
Journal of Medical Virology
Volume 82, Issue 7, pages 1186–1191, July 2010
How to Cite
Cuzick, J., Ambroisine, L., Cadman, L., Austin, J., Ho, L., Terry, G., Liddle, S., Dina, R., McCarthy, J., Buckley, H., Bergeron, C., Soutter, W.P., Lyons, D. and Szarewski, A. (2010), Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. J. Med. Virol., 82: 1186–1191. doi: 10.1002/jmv.21801
- Issue published online: 25 MAY 2010
- Article first published online: 25 MAY 2010
- Manuscript Accepted: 11 FEB 2010
- Gen-Probe Incorporated
- Genomica S.A.U
- mtm Laboratories
- Roche Diagnostics
- HPV testing;
- cervical screening;
- Abbott RealTime high-risk HPV test;
HPV DNA testing is known to be much more sensitive than cytology, but less specific. A range of HPV and related tests in 858 women referred for colposcopy because of an abnormal smear were evaluated to compare the performances of these tests. This article compared the Abbott test to other tests which had been previously evaluated. This test was a real true test for 14 high-risk HPV types. The Abbott test was found to be highly sensitive for cervical intraepithelial neoplasia grade 3 or worse (CIN3+) (98.9%) with a specificity of 31.5%. These numbers were comparable with the Qiagen HC2 test, the Roche Linear Array and Amplicor tests, and the Gen-Probe APTIMA test. Differences between these tests appeared to be related mostly to the choice of cutoff level. An added feature of the Abbott test was the provision of type specific results for HPV 16 and 18. J. Med. Virol. 82: 1186–1191, 2010. © 2010 Wiley-Liss, Inc.